[go: up one dir, main page]

WO2014082354A1 - 西达本胺的晶型及其制备方法与应用 - Google Patents

西达本胺的晶型及其制备方法与应用 Download PDF

Info

Publication number
WO2014082354A1
WO2014082354A1 PCT/CN2012/086841 CN2012086841W WO2014082354A1 WO 2014082354 A1 WO2014082354 A1 WO 2014082354A1 CN 2012086841 W CN2012086841 W CN 2012086841W WO 2014082354 A1 WO2014082354 A1 WO 2014082354A1
Authority
WO
WIPO (PCT)
Prior art keywords
chidamide
crystal form
weight ratio
preparation
water
Prior art date
Application number
PCT/CN2012/086841
Other languages
English (en)
French (fr)
Inventor
鲁先平
李志斌
Original Assignee
深圳微芯生物科技有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RS20181175A priority Critical patent/RS57856B1/sr
Priority to US14/646,371 priority patent/US9573901B2/en
Priority to CA2891006A priority patent/CA2891006C/en
Priority to DK12889061.3T priority patent/DK2930169T3/en
Priority to JP2015543237A priority patent/JP6387011B2/ja
Priority to ES12889061.3T priority patent/ES2691395T3/es
Priority to EP12889061.3A priority patent/EP2930169B1/en
Priority to RU2015123682/04A priority patent/RU2603138C1/ru
Priority to SI201231417T priority patent/SI2930169T1/sl
Priority to KR1020157014782A priority patent/KR20150082490A/ko
Application filed by 深圳微芯生物科技有限责任公司 filed Critical 深圳微芯生物科技有限责任公司
Priority to BR112015011898-4A priority patent/BR112015011898B1/pt
Priority to PL12889061T priority patent/PL2930169T3/pl
Priority to AU2012395573A priority patent/AU2012395573C1/en
Publication of WO2014082354A1 publication Critical patent/WO2014082354A1/zh
Priority to HK15111090.9A priority patent/HK1210176A1/zh
Priority to HRP20181704TT priority patent/HRP20181704T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to the field of medicinal chemistry, and in particular to novel forms A and B of sidabenamine and preparation methods and applications thereof.
  • Sidabenamine, English name Chidamide, is a new type of anticancer drug with a new chemical structure and global intellectual property independently designed and synthesized by Shenzhen Microcore Biotechnology Co., Ltd. Its chemical name is N-(2- Amino-4-fluorophenyl)-4-(N-(3-pyridineacryloyl)aminoindenyl)benzamide, the chemical structure of which is
  • citadine has a histone deacetylase inhibitory activity and can be used for the treatment of diseases associated with differentiation and proliferation, such as cancer and psoriasis, especially for blood and solid tumors. Excellent efficacy.
  • Crystal form is one of the important factors affecting the quality of the drug, the efficacy and the processing properties of the formulation.
  • the polymorphic phenomenon refers to the same compound, and by controlling different generation conditions, two or more kinds of molecular spatial arrangement modes can be formed, thereby generating different solid crystals.
  • Drug polymorphism is a common phenomenon in drug development and an important factor affecting drug quality. Different crystal forms of the same compound have the same chemical composition, but the microscopic crystal structure is different, which leads to their appearance and physicochemical properties. There are differences in quality and biological activity. Different crystal forms of drugs often have different solubility, storage stability, water absorption, density, and bioavailability.
  • the crystalline form of the drug directly affects the quality of the pharmaceutical formulation of the drug, the absorption behavior in the human body, and ultimately the benefit ratio of the therapeutic effect and side effects produced by the formulation in the human body. Therefore, it is of great significance to study the homomorphic polymorphism of drugs and the preparation methods of different crystal forms. Summary of the invention
  • the object of the present invention is to study, discover and provide a novel crystal form of sitda amide by a crystallographic method and a preparation method and application thereof.
  • the sidabenamine prepared according to Example 2 described in the patent ZL03139760.3 is inferior in purity (about 95%).
  • the results of LC/MS analysis are shown in Figure 1, which indicates that the product contains 4.7% of the structure of formula II as N-(2-amino-5-fluorophenyl)-4-(N-(3-pyridineacryloyl). Aminoguanidino)benzamide.
  • the results of the NMR analysis are shown in Figure 2, which indicates that the product contains 1.80% tetrahydrofuran, far exceeding the 0.072% residual solvent specified in the International Conference of Harmonizition (ICH).
  • the present invention has studied, discovered and provided two crystalline forms of citapiline by crystallographic methods, namely, cidabenamine form A and cidabenamine form B.
  • the present invention employs the internationally recognized X-ray powder diffraction method (XRPD) to study and characterize new crystalline forms of citalopram.
  • the substantially pure sidabenamine crystalline form provided by the present invention has an X-ray powder diffraction pattern as shown in FIG. 3, and has the following characteristics:
  • the X-ray powder diffraction pattern has a reflection angle of about 2.18°, 6.61. °, 8.42 °, 12.69 °, 17.85 °, 18.34 °, 19.27 °, 20.10 °, 20.59 °, 21.58 °, 23.70 °, 23.96. 25.52. , 27.00. 27.90. , 29.59. There are characteristic peaks at 29.94 °.
  • the present invention also employs infrared spectroscopy (IR) to study and characterize the new crystalline form of sidabenamine.
  • Instrument FT-IR NICOLET 6700 (USA).
  • Determination method KBr tableting method, the spectral range is 400 cm _1 -4000 cm" 1 , the resolution is 4 cm" 1 .
  • the substantially pure sidabenamine crystal form A provided by the present invention has an infrared photogram as shown in FIG. 4, and has the following characteristics: its infrared spectrum is about 3412, 3282, 3199, 3043, 1654, 1615, 1524. There are characteristic absorption peaks at 1 , 1514, 1497, 1442, 1418, 1332, 1296, 1234, 1198, 1183, 1166 and 1027 cm".
  • the crystal form can also be characterized by other analytical techniques well known in the art. For example, differential scanning calorimetry (DSC). Instrument: DSC 204 Germany), heating rate: 10 ° C / min, nitrogen flow rate: 20 mL / min.
  • DSC differential scanning calorimetry
  • the substantially pure cidabenamine crystal form A provided by the present invention has a differential scanning calorimetry analysis curve as shown in Fig. 5, which has the following characteristics:
  • the differential scanning calorimetry curve has a curve at about 239.4 °C. Endothermic peak.
  • the substantially pure citabenamine form B provided by the present invention has an X-ray powder diffraction pattern as shown in Fig. 6, which has the following characteristics:
  • the X-ray powder diffraction pattern has a reflection angle of about 2.18°, 8.43. °, 12.65. , 16.90. , 17.83. , 19.47. 20.13. , 20.58. 21.22 °, 21.54 °, 21.92 °, 23.94 °, 25.55. 26.98. 27.92. , 29.58 ° and 29.90.
  • the infrared spectrum of the substantially pure cidabenamine crystal form B provided by the present invention is shown in Fig. 7, which has the following characteristics: its infrared spectrum is about 3412, 3327, 3272, 3196, 3043, 1653, 1619, 1570. There are characteristic absorption peaks at 1515, 1496, 1444, 1419, 1331, 1357, 1296, 1278, 1267, 1232, 1198, 1184, 1166 and 1038 cm -1 .
  • the substantially pure sitdabenamine Form B provided by the present invention has a differential scanning calorimetry curve as shown in Figure 8, which has the following characteristics:
  • the differential scanning calorimetry curve is about 214.1 ° C and 241.2. There is an endothermic peak at °C.
  • the X-ray powder diffraction pattern may be 2 ⁇ A slight change, the value may differ by about 1 unit, or about 0.8 units, or about 0.5 units, or about 0.3 units, or about 0.1 units, so the value given cannot be considered absolute.
  • Experimental Results Surface the present invention has a good performance in terms of solubility and a high bioavailability of the crystal form A and the cidabenamine form B of the present invention.
  • the present invention also provides a process for the preparation of Form A and Form B of Sidabenamine with high purity (>99%) and no residual solvent.
  • the preparation method of the cidabenamine crystal form A provided by the invention comprises:
  • Step 1 Add sitdaben to 2 mol/L of dilute hydrochloric acid, stir and dissolve at room temperature, add water to dilute the solution, then add 2 mol/L sodium hydroxide solution to the solution, stir for 30 minutes, and filter; 1
  • the weight ratio of cidabenamine to dilute hydrochloric acid is 1:4.2 ⁇ 1:4.4, the weight ratio of cidabenamine to water is 1:25-1:30, the cidabenamine and sodium hydroxide
  • the weight ratio of the solution is 1: 2.5 ⁇ 1:2.7;
  • Step 2 collecting and filtering the solid obtained by adding to the water, adding 2 mol/L sodium hydroxide solution, stirring for 60 minutes, and filtering; collecting the solid obtained by filtration, washing with water until the pH of the washing liquid is 5-7, and drying; 2
  • the weight ratio of cidabenamine to water is 1:15 ⁇ 1:25, and the weight ratio of cidabenamine to sodium hydroxide solution is 1:1.5 ⁇ 1:2.0.
  • the drying in step 2 is vacuum drying at 80 ° C for 24 hours.
  • the invention provides a method for preparing cidabenamine crystal form B.
  • the crystal form A of cidabenamine is added to dimethyl sulfoxide, stirred and dissolved at room temperature, then water is added dropwise, stirred for 30 minutes, filtered, and the obtained solid is dried.
  • the weight ratio of the cidabenamine crystal form A to the dimercapto sulfoxide is 1:10 ⁇ 1:20
  • the weight ratio of the cidabenamine crystal form A to water is 1:100 ⁇ 1 :200.
  • the drying is vacuum drying at 80 ° C for 24 hours.
  • the preparation method of the crystal form A and the crystal form B of the present invention is as follows: the content of the crystal form A and the form B are both >99.0%.
  • the cidabenamine form A and the cidabenamine form B of the present invention are excellent in oral absorption and inhibition of cell differentiation and proliferation, and are weak in toxicity, have good storage and processing stability, and are usable.
  • the present invention therefore provides the use of said sitabenamine Form A and Citadine Amorphine Form B for the manufacture of a medicament for the treatment of a disease associated with cell differentiation and proliferation.
  • the disease associated with cell differentiation and proliferation is cancer or psoriasis, and the cancer includes blood cancer or solid tumor.
  • novel crystalline form of cidabenamine of the present invention can be further prepared into various solid dosage forms of oral drugs such as tablets, capsules or granules.
  • the pharmaceutical preparation for treating a disease associated with cell differentiation and proliferation comprises the above-described cidabenamine form A or / and the citadine-based form B and a pharmaceutically acceptable adjuvant. That is, in some embodiments the pharmaceutical formulation comprises citapiline Form A and a pharmaceutical excipient; in some embodiments the pharmaceutical formulation comprises citapiline Form B and a pharmaceutical excipient;
  • the pharmaceutical preparations described in the examples include a mixture of cidabenamine Form A and Cidabenamine Form B, and a pharmaceutically acceptable adjuvant.
  • the formulation contains 5 to 20% of cidabenamine Form A or / and Citadine A Form B and 80 to 95% of a pharmaceutical excipient.
  • the active compound is mixed with at least one pharmaceutically acceptable inert excipient or carrier, such as sodium citrate, calcium phosphate, fillers, binders, humectants, disintegrating agents, retarders, Absorption enhancers, wetting agents, absorbents or lubricants and mixtures thereof.
  • fillers such as starch, lactose, sucrose, glucose, mannitol and silicic acid; binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; humectants such as glycerin; Decomposing agents such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates and sodium carbonate, low-substituted hydroxypropyl cellulose; retarder solutions such as paraffin; absorption enhancers such as quaternary amines; Wetting agents such as cetyl alcohol and glyceryl monostearate; absorbents such as kaolin and bentonite; lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate.
  • binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone,
  • Figure 1 shows an HPLC chromatogram of the solid obtained in Example 2 according to the patent ZL03139760.3
  • Figure 2 shows a 3 ⁇ 4 NMR spectrum of the solid obtained in Example 2 according to the patent ZL03139760.3;
  • Fig. 3 is a view showing an X-ray powder diffraction pattern of the crystal form A of cidabenamine provided in Example 1 of the present invention, which was obtained by irradiation with copper ⁇ rays.
  • the ordinate indicates the diffraction intensity expressed in counts per second (cps), and the abscissa indicates the diffraction angle expressed in degrees 2 ⁇ ;
  • FIG. 4 is an infrared optical map of the crystal form A of the present invention provided by the embodiment 1 of the present invention, wherein the ordinate is the light transmittance (T), the unit is the percentage (%); the abscissa is the wave number, and the unit is cm- 1. ;
  • Figure 5 is a differential scanning calorimetry (DSC) showing the crystal form A of cidabenamine provided in Example 1 of the present invention.
  • the graph the ordinate is the heat flow rate, the unit is card / sec; the abscissa is the temperature, the unit is. C ;
  • Fig. 6 is a view showing the X-ray powder diffraction pattern of the crystal form B of the present invention provided in Example 3 of the present invention, which was obtained by irradiation with copper ⁇ ray.
  • the ordinate indicates the diffraction intensity expressed in counts per second (cps), and the abscissa indicates the diffraction angle expressed in degrees 2 ⁇ ;
  • Figure 8 is a differential scanning calorimetry (DSC) graph of the crystal form B of the present invention provided in Example 3 of the present invention, wherein the ordinate is the heat flow rate in units of calories per second; the abscissa is temperature in units of ° C. detailed description
  • the embodiment of the invention discloses the crystal form of sidabenamine and a preparation method and application thereof. Those skilled in the art can learn from the contents of this paper and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
  • the method of the present invention has been described by the preferred embodiments, and it is obvious that those skilled in the art can make and modify and combine the methods described herein to implement and apply the present invention without departing from the scope of the present invention. .
  • Infrared spectroscopy test conditions Instrument: FT-IR NICOLET 6700 (USA); KBr tableting method.
  • Differential Scanning Calorimetry Test Conditions: Instrument: DSC 204 (Germany); Heating Rate: 10 °C/min; Nitrogen Flow Rate: 20 mL/min Instrument: DSC 204 (Germany); Heating Rate: 10 °C/min; Nitrogen Flow Rate: 20 mL/min.
  • Preparation process Weigh the prescribed amount of sidaben A, lactose, soluble starch, microcrystalline cellulose and sodium carboxymethyl starch, mix evenly, make soft material with proper amount of water as wetting agent, use 20 mesh sieve The wet granules were dried at 60 ° C, sized with a 18 mesh sieve, and the talc powder was added in a prescribed amount, and the mixture was uniformly mixed, and the tablets were obtained.
  • Sidabenamine Form A is passed through a 100 mesh sieve, and microcrystalline cellulose, lactose, sodium carboxymethyl starch and magnesium stearate are sieved through an 80 mesh sieve to weigh the prescribed amount of microcrystalline cellulose and lactose. Mix well with sodium carboxymethyl starch, and then mix the crystal form A of sidaben with the same amount of addition method, add the prescription amount of magnesium stearate, and mix the capsule.
  • Example 5 Preparation of Sidabenamine Form A Granules
  • Preparation process Weigh the prescribed amount of sidaben A, lactose, soluble starch, microcrystalline cellulose and sodium carboxymethyl starch, mix evenly, make soft material with proper amount of water as wetting agent, use 20 mesh sieve The wet granules were dried at 60 ° C, and granulated with a 18 mesh sieve.
  • Example 6 Preparation of Sidabenamine Form B Tablet
  • Talc Preparation process Weigh the prescribed amount of cidabenamine crystal form B, lactose, soluble starch, microcrystalline cellulose and sodium carboxymethyl starch, mix evenly, make soft material with proper amount of water as wetting agent, use 20 mesh sieve The wet granules were dried at 60 ° C, sized with a 18 mesh sieve, and the talc powder was added in a prescribed amount, and the mixture was uniformly mixed, and the tablets were obtained.
  • Example 7 Preparation of Sidabenamine Form B Capsule
  • Sidabenamine Form B is passed through a 100 mesh sieve, and microcrystalline cellulose, lactose, sodium carboxymethyl starch and magnesium stearate are sieved through an 80 mesh sieve to weigh the prescribed amount of microcrystalline cellulose and lactose. Mix well with sodium carboxymethyl starch, and then mix the crystal form A of sidaben with the same amount of addition method, add the prescription amount of magnesium stearate, and mix the capsule.
  • Example 8 Preparation of Sidabenamine Form B Granules
  • Preparation process Weigh the prescribed amount of cidabenamine crystal form B, lactose, soluble starch, microcrystalline cellulose and sodium carboxymethyl starch, mix evenly, make soft material with proper amount of water as wetting agent, use 20 mesh sieve The wet granules were dried at 60 ° C, and granulated with a 18 mesh sieve.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明属于药物化学领域，公开了西达本胺的二种结晶形式即西达本胺晶型A和西达本胺晶型B，以及西达本胺的新的结晶形式的制备方法。本发明所述西达本胺晶型A和西达本胺晶型B可用于制备治疗与细胞分化和增殖相关的疾病的药物。

Description

西达本胺的晶型及其制备方法与应用 本申请要求于 2012 年 11 月 27 日提交中国专利局、 申请号为 201210489178.8、发明名称为"西达本胺的晶型及其制备方法与应用"的中国专 利申请的优先权， 其全部内容通过引用结合在本申请中。 技术领域
本发明涉及药物化学领域， 具体涉及西达本胺的新晶型 A、 B及其制备方 法与应用。
背景技术
西达本胺， 英文名为 Chidamide, 是由深圳微芯生物科技有限责任公司自 主设计和合成的具有全新化学结构和全球知识产权的一种新型抗癌药物,其化 学名称为 N-(2-氨基 -4-氟苯基 )-4-(N-(3-吡啶丙烯酰基)氨曱基)苯曱酰胺， 其化 学结构如结构式 I所
Figure imgf000002_0001
如专利 ZL03139760.3和 US7,244,751所述， 西达本胺具有组蛋白去乙酰 化酶抑制活性， 可以用于治疗与分化和增殖相关的疾病， 如癌症和牛皮癣， 尤其对血癌和实体瘤具有优异疗效。
专利 ZL03139760.3和 US7,244,751公开了西达本胺的制备方法， 但并未 说明所得产品是否为晶体物质， 也没有说明该化合物是否存在同质多晶现象。 在上述专利中， 对该化合物活性的评价不是在固态进行的， 因此， 也没有公 开任何与晶体特性有关的说明。
晶型是影响药物质量、 疗效和制剂加工性能的重要因素之一。 多晶型现 象， 是指同一化合物， 通过控制其不同的生成条件， 可形成两种或两种以上 的分子空间排列方式， 从而产生不同的固体结晶的现象。 药物多晶型是药品 研发中的常见现象， 是影响药品质量的重要因素。 同一化合物的不同晶型， 其化学组成相同， 但微观晶体结构不同， 因而导致它们在外观形态、 理化性 质和生物活性上存在差异。 药物的不同晶型往往具有不同的溶解性、 储存稳 定性、 吸水性、 密度和生物利用度。 药物的晶型直接影响药物的药用制剂的 质量、 在人体的吸收行为并最终影响该制剂在人体中产生的治疗效果和副作 用的获益比。 因此， 研究药物的同质多晶现象以及不同晶型的制备方法具有 重要的意义。 发明内容
有鉴于此， 本发明目的是通过晶体学的方法， 研究、 发现并提供西达本 胺的新的晶型及其制备方法与应用。
按照专利 ZL03139760.3所述的实施例 2所制得的西达本胺纯度较差 (约 95% )。 LC/MS分析结果如图 1所示， 表明产品中含有 4.7%的式 II所示结构 的 N-(2-氨基 -5-氟苯基 )-4-(N-(3-吡啶丙烯酰基)氨曱基)苯曱酰胺。 NMR分 析结果如图 2所示，表明产品中含有 1.80%的四氢呋喃，远远超出了人用药品 注册技术要求国际十办调会议 ( ICH, International Conference of Harmonizition ) 规定的 0.072%残留溶剂 造。
Figure imgf000003_0001
本发明通过晶体学的方法， 研究、 发现并提供了西达本胺的二种结晶形 式， 即西达本胺晶型 A和西达本胺晶型 B。
本发明采用国际上公认的 X-射线粉末衍射法 （XRPD ) 来研究和表征西 达本胺的新的结晶形式。 仪器设备： D/MAX-1200型 X-射线粉末衍射仪。 测 定条件与方法： Cu/K-alphal (靶）， 40KV-40 mA (工作电压与电流）， I ( max ) =2244, 2θ=5-60度（扫描范围）, 0.005/0.06sec. (扫描速度)， λ=1.54056。
本发明提供的基本上纯净的西达本胺晶型 Α, 其 X-射线粉末衍射图如图 3所示， 其具有如下特性： 其 X-射线粉末衍射图在反射角 2Θ约 4.18°、 6.61 °、 8.42 °、 12.69°、 17.85 °、 18.34°、 19.27 °、 20.10 °、 20.59°、 21.58 °、 23.70° 、 23.96。、 25.52。、 27.00。、 27.90。、 29.59。和 29.94 °处有特征峰。
本发明还采用红外光谱法 （IR ) 来研究和表征了西达本胺的新的结晶形 式。 仪器： FT-IR NICOLET 6700 (美国）。 测定方法： KBr压片法， 光谱范围 400 cm_1-4000 cm"1 , 分辨率为 4 cm"1。
本发明提供的基本上纯净的西达本胺晶型 A, 其红外光语图如图 4所示， 其具有如下特性： 其红外光谱在约 3412、 3282、 3199、 3043、 1654、 1615、 1524、 1514、 1497、 1442、 1418、 1332、 1296、 1234、 1198、 1183、 1166 和 1027cm"1处有特征吸收峰。
晶型也可以用技术上公知的其他分析技术表征。 例如差示扫描量热法 ( DSC )。仪器： DSC 204 德国），升温速率： 10°C/min,氮气流速： 20mL/min。
本发明提供的基本上纯净的西达本胺晶型 A, 其差示扫描量热分析曲线 如图 5所示，其具有如下特性： 其差示扫描量热分析曲线在约 239.4 °C处有吸 热峰。
本发明提供的基本上纯净的西达本胺晶型 B, 其 X-射线粉末衍射图如图 6所示， 其具有如下特性： 其 X-射线粉末衍射图在反射角 2Θ约 4.18°、 8.43 °、 12.65。、 16.90。、 17.83。、 19.47。、 20.13。、 20.58。、 21.22 °、 21.54 °、 21.92 °、 23.94° 、 25.55。、 26.98。、 27.92。、 29.58 °和 29.90。处有特征峰。
本发明提供的基本上纯净的西达本胺晶型 B其红外光谱图如图 7所示， 其具有如下特性： 其红外光谱在约 3412、 3327、 3272、 3196、 3043、 1653、 1619、 1570、 1515、 1496、 1444、 1419、 1331、 1357、 1296、 1278、 1267、 1232、 1198、 1184、 1166和 1038cm-1处有特征吸收峰。
本发明提供的基本上纯净的西达本胺晶型 B其其差示扫描量热分析曲线 如图 8 所示， 其具有如下特性： 其差示扫描量热分析曲线在约 214.1 °C 和 241.2°C处有吸热峰。
值得注意的是， 对于以上所述晶型的 X-射线粉末衍射峰， 在一台机器和 另一台机器之间以及一个样品和另一个样品之间， X-射线粉末衍射图谱的 2Θ 可能会略有变化， 其数值可能相差大约 1个单位， 或者相差大约 0.8个单位， 或者相差大约 0.5个单位， 或者相差大约 0.3个单位， 或者相差大约 0.1个单 位， 因此所给出的数值不能视为绝对的。 实验结果表面， 本发明所述西达本胺晶型 A和西达本胺晶型 B在溶解度 方面具有良好的性能， 从而生物利用度高。
本发明还提供了纯度高（ >99% )且不含残留溶剂的西达本胺晶型 A和晶 型 B制备方法。
本发明提供的西达本胺晶型 A的制备方法为包括：
步骤 1 :将西达本胺加入 2 mol/L的稀盐酸中， 室温搅拌溶解后加水稀译， 然后所得溶液中滴加 2 mol/L 的氢氧化钠溶液， 搅拌 30分钟， 过滤； 其中步 骤 1所述西达本胺与稀盐酸的重量比 1:4.2〜1:4.4,所述西达本胺与水的重量比 1： 25-1:30, 所述西达本胺与氢氧化钠溶液的重量比为 1 : 2.5〜1:2.7；
步骤 2: 收集过滤所得固体加入水中， 滴加 2 mol/L 的氢氧化钠溶液， 搅 拌 60分钟， 过滤； 收集过滤所得固体， 水洗至洗涤液 pH值为 5〜7后干燥即 得； 其中步骤 2所述西达本胺与水的重量比为 1： 15〜1:25, 所述西达本胺与氢 氧化钠溶液的重量比为 1： 1.5〜1:2.0。
作为优选， 步骤 2所述干燥为 80 °C真空干燥 24小时。
本发明提供的西达本胺晶型 B的制备方法， 将西达本胺晶型 A加入二曱 基亚砜中， 室温搅拌溶解， 然后滴加水， 搅拌 30分钟， 过滤， 收集所得固体 干燥即得； 其中， 所述西达本胺晶型 A与二曱基亚砜的重量比 1 ： 10〜1 :20, 所述西达本胺晶型 A与水的重量比为 1： 100〜1:200。
作为优选， 所述干燥为 80°C真空干燥 24小时。
本发明所述西达本胺晶型 A和晶型 B制备方法得到晶型 A和晶型 B含量 均 >99.0%。
本发明所述西达本胺晶型 A 和西达本胺晶型 B 在高温 （60°C )、 高湿 ( 90%±5% )和强光照射（ 4500Lx±500Lx ) 下进行稳定性试验， 试验结果表 明： 西达本胺晶体 A和西达本胺晶型 B均保持原有晶型不变， 含量和杂质总 量亦未发生明显改变。 西达本胺晶体 A和西达本胺晶型 B均适合药剂制造和 长期储存。 本发明所述西达本胺晶型 A和西达本胺晶型 B在口服吸收性和抑 制细胞的分化和增殖的方面性能优异， 并且其毒性弱， 具有良好的储存和处 理稳定性， 可用于制备治疗与细胞分化和增殖相关的疾病的药物。 因此本发 明提供了所述的西达本胺晶型 A和西达本胺晶型 B在制备用于治疗与细胞分 化和增殖相关的疾病的药物中的应用。 进一步的， 所述与细胞分化和增殖相关的疾病为癌症或牛皮癣， 所述癌 症包括血癌或实体瘤。
本发明所述西达本胺新晶型可以进一步制备成口服药的各种固体剂型， 如片剂， 胶嚢剂或颗粒剂。
本发明所述用于治疗与细胞分化和增殖相关的疾病的药用制剂， 包括所 述西达本胺晶型 A或 /和所述西达本胺晶型 B以及药用辅料。即在一些实施例 中所述药用制剂包括西达本胺晶型 A和药用辅料； 在一些实施例中所述药用 制剂包括西达本胺晶型 B 和药用辅料； 在另一些实施例中所述药用制剂包括 西达本胺晶型 A和西达本胺晶型 B的混合物以及药用辅料。
在一些具体实施例中所述制剂含 5〜20%的西达本胺晶型 A或 /和西达本胺 晶型 B以及 80〜95%的药用辅料。在这些剂型中， 活性化合物与至少一种药学 上可接受的惰性赋形剂或载体混合， 如柠檬酸钠、 磷酸钙、 填充剂、 粘合剂、 保湿剂、 崩解剂、 阻滞剂、 吸收促进剂、 湿润剂、 吸收剂或润滑剂及它们的 混合物。 其中， 填充剂如淀粉， 乳糖， 蔗糖， 葡萄糖， 甘露醇和硅酸； 粘合 剂如羧曱基纤维素， 藻酸盐， 明胶， 聚乙烯吡咯酮， 蔗糖和阿拉伯胶； 保湿 剂如甘油； 崩解剂如琼脂， 碳酸钙， 土豆淀粉或木薯淀粉， 海藻酸， 某些硅 酸盐和碳酸钠， 低取代羟丙基纤维素； 阻滞剂溶液如石蜡； 吸收促进剂如季 胺类化合物； 湿润剂如十六醇和单硬脂酸甘油酯； 吸收剂如白陶土和皂土； 润滑剂如滑石粉， 硬脂酸钙， 硬脂酸镁， 固体聚乙二醇， 月桂硫酸钠。 附图说明
图 1示按照专利 ZL03139760.3所述的实施例 2制得的固体的 HPLC图谱； 图 2示按照专利 ZL03139760.3所述的实施例 2制得的固体的 ¾ NMR图 谱；
图 3示本发明实施例 1提供的西达本胺晶型 A的 X-射线粉末衍射图， 其 通过用铜 Κα射线照射获得。 在 X-射线粉末衍射图中， 纵坐标表示用计数 /秒 ( cps )表示的衍射强度， 横坐标表示用度表示的衍射角 2Θ;
图 4示本发明实施例 1提供的西达本胺晶型 A的红外光语图， 纵坐标为 透光率 (T) , 单位为百分率（％)； 横坐标为波数， 单位为 cm-1;
图 5示本发明实施例 1提供的西达本胺晶型 A的差示扫描量热法 ( DSC ) 曲线图， 纵坐标为热流率， 单位为卡 /秒； 横坐标为温度， 单位为。 C ;
图 6示本发明实施例 3提供的西达本胺晶型 B的 X-射线粉末衍射图， 其 通过用铜 Κα射线照射获得。 在 X-射线粉末衍射图中， 纵坐标表示用计数 /秒 ( cps )表示的衍射强度， 横坐标表示用度表示的衍射角 2Θ;
图 7示本发明实施例 3提供的西达本胺晶型 B的红外光语图， 纵坐标为 透光率 (T) , 单位为百分率（％)； 横坐标为波数， 单位为 cm-1;
图 8示本发明实施例 3提供的西达本胺晶型 B的差示扫描量热法 ( DSC ) 曲线图， 纵坐标为热流率， 单位为卡 /秒； 横坐标为温度， 单位为 °C。 具体实施方式
本发明实施例公开了西达本胺的晶型及其制备方法与应用。 本领域技术 人员可以借鉴本文内容， 适当改进工艺参数实现。 特别需要指出的是， 所有 类似的替换和改动对本领域技术人员来说是显而易见的， 它们都被视为包括 在本发明。 本发明的方法已经通过较佳实施例进行了描述， 相关人员明显能 在不脱离本发明内容、 精神和范围内对本文所述的方法进行改动或适当变更 与组合， 来实现和应用本发明技术。
为了进一步理解本发明， 下面结合实施例对本发明进行详细说明。 其中 本发明所述的百分比除特别注明外， 均为重量百分比。 说明书中所描述的数 值范围， 如计量单位、 反应条件、 化合物物理状态或百分比， 均是为了提供 明白无误的书面参考。 本领域熟练技术人员在实践本专利时， 使用在此范围 之外或有别于单个数值的温度、 浓度、 数量等， 仍然可以得到预期的结果。
试验方法：
X-射线粉末衍射测试条件： 仪器： D/MAX-1200 (日本）； 辐射源： Cu-Ka ( 40 kV、 40 mA )。
红外光谱测试条件： 仪器： FT-IR NICOLET 6700 (美国）； KBr压片法。 差示扫描量热分析测试条件：仪器： DSC 204(德国）；升温速率： 10°C/min; 氮气流速： 20mL/min„
质子核磁共振测试条件： 仪器： AV-400 (德国）； 溶剂： DMSO-d6。 实施例 1: 西达本胺晶型 A的制备
将 4.84kg西达本胺 (纯度约 95% )加入 20.91kg 2 mol/L的稀盐酸中， 室 温搅拌溶解，加入 137.8kg水，搅拌 5分钟。向所得溶液中滴加 21.35kg 2 mol/L 的氢氧化钠溶液， 搅拌 30分钟， 过滤。 将所得固体加入 96.70kg水中， 滴加 8.39kg 2 mol/L 的氢氧化钠溶液， 搅拌 60分钟， 过滤， 水洗至滤液 pH值为 5〜7。 将所得固体于 80°C真空干燥 24小时， 得到 4.32kg西达本胺晶型 A, 含 量 99.2%。 该晶型的 X-射线粉末衍射图、 红外光谱、 差示扫描量热分析曲线 分别如图 3、 图 4、 图 5所示。 实施例 2: 西达本胺晶型 B的制备
将 lg西达本胺晶型 A加入 10mL二曱基亚砜中， 室温搅拌溶解。 向所得 溶液中滴加 lOOmL水， 搅拌 30分钟， 过滤。 将所得固体于 80°C真空干燥 24 小时， 得到西达本胺晶型 B, 含量 99.2%。 该晶型的 X-射线粉末衍射图、 红 外光谱、 差示扫描量热分析曲线分别如图 6、 图 7、 图 8所示。 实施例 3 ： 西 胺晶型 A片剂的制备
处方 （ 1000片）：
西达本胺晶型 A
可溶性淀粉
乳糖
微晶纤维素
羧曱基淀粉钠
滑石粉
制备工艺： 称取处方量的西达本胺晶型 A、 乳糖、 可溶性淀粉、 微晶纤 维素和羧曱基淀粉钠， 混合均匀， 以适量水为润湿剂制软材， 用 20目筛制湿 颗粒， 于 60°C干燥， 用 18目筛整粒， 加入处方量的滑石粉， 混合均匀， 压片 即得。
实施例 4: 西达本胺晶型 A胶嚢剂的制备
处方 （ 1000粒）： 西达本胺晶型 A
微晶纤维素
乳糖
羧曱基淀粉钠
硬脂酸镁
制备工艺： 将西达本胺晶型 A过 100 目筛， 将微晶纤维素、 乳糖、 羧曱 基淀粉钠和硬脂酸镁过 80目筛， 称取处方量的微晶纤维素、 乳糖和羧曱基淀 粉钠， 混合均匀, 然后将西达本胺晶型 A与其按等量递加法混勾， 加入处方 量硬脂酸镁混匀， 灌装胶嚢即得。 实施例 5: 西达本胺晶型 A颗粒剂的制备
处方 ( 1000包）：
西达本胺晶型 A 5 g
可溶性淀粉 500g
乳糖 200g
微晶纤维素 175 g
羧曱基淀粉钠 100 g
制备工艺： 称取处方量的西达本胺晶型 A、 乳糖、 可溶性淀粉、 微晶纤 维素和羧曱基淀粉钠， 混合均匀， 以适量水为润湿剂制软材， 用 20目筛制湿 颗粒， 于 60°C干燥， 用 18目筛整粒， 分装即得。 实施例 6: 西达本胺晶型 B片剂的制备
处方 （ 1000片）：
西达本胺晶型 B
可溶性淀粉
乳糖
微晶纤维素
羧曱基淀粉钠
滑石粉 制备工艺： 称取处方量的西达本胺晶型 B、 乳糖、 可溶性淀粉、 微晶纤 维素和羧曱基淀粉钠， 混合均匀， 以适量水为润湿剂制软材， 用 20目筛制湿 颗粒， 于 60°C干燥， 用 18目筛整粒， 加入处方量的滑石粉， 混合均匀， 压片 即得。 实施例 7: 西达本胺晶型 B胶嚢剂的制备
处方 （ 1000粒）：
西达本胺晶型 B
微晶纤维素
乳糖
羧曱基淀粉钠
硬脂酸镁
制备工艺： 将西达本胺晶型 B过 100目筛， 将微晶纤维素、 乳糖、 羧曱基 淀粉钠和硬脂酸镁过 80目筛， 称取处方量的微晶纤维素、 乳糖和羧曱基淀粉 钠， 混合均匀, 然后将西达本胺晶型 A与其按等量递加法混勾， 加入处方量 硬脂酸镁混匀， 灌装胶嚢即得。 实施例 8: 西达本胺晶型 B颗粒剂的制备
处方 （ 1000包）：
西达本胺晶型 B 5 g
可溶性淀粉 500g
乳糖 200g
微晶纤维素 175 g
羧曱基淀粉钠 100 g
制备工艺： 称取处方量的西达本胺晶型 B、 乳糖、 可溶性淀粉、 微晶纤 维素和羧曱基淀粉钠， 混合均匀， 以适量水为润湿剂制软材， 用 20目筛制湿 颗粒， 于 60°C干燥， 用 18目筛整粒， 分装即得。 以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。 应当 指出， 对于本技术领域的普通技术人员来说， 在不脱离本发明原理的前提下， 还可以对本发明进行若干改进和修饰， 这些改进和修饰也落入本发明权利要 求的保护范围内。

Claims

权 利 要 求
1、 西达本胺晶型 A, 其特征在于， 其 X-射线粉末衍射图在反射角 2Θ约 4.18°、 6.61 °、 8.42 °、 12.69 °、 17.85 °、 18.34 °、 19.27 °、 20.10 °、 20.59 °、 21.58 。、 23.70° 、 23.96。、 25.52。、 27.00。、 27.90。、 29.59。和 29.94。处有特征峰; 其红外光谱在约 3412、 3282、 3199、 3043、 1654、 1615、 1524、 1514、 1497、 1442、 1418、 1332、 1296、 1234、 1198、 1183、 1166和 1027cm 处有特征吸 收峰； 其差示扫描量热分析曲线在约 239.4 °C处有吸热峰。
2、 权利要求 1所述的西达本胺晶型 A的制备方法， 其特征在于， 包括： 步骤 1 :将西达本胺加入 2 mol/L的稀盐酸中， 室温搅拌溶解后加水稀译， 然后所得溶液中滴加 2 mol/L 的氢氧化钠溶液， 搅拌 30分钟， 过滤； 其中步 骤 1所述西达本胺与稀盐酸的重量比 1 :4.2〜1 :4.4,所述西达本胺与水的重量比 1： 25-1 :30, 所述西达本胺与氢氧化钠溶液的重量比为 1 : 2.5〜1 :2.7；
步骤 2: 收集过滤所得固体加入水中， 滴加 2 mol/L 的氢氧化钠溶液， 搅 拌 60分钟， 过滤； 收集过滤所得固体， 水洗至洗涤液 pH值为 5〜7后干燥即 得； 其中步骤 2所述西达本胺与水的重量比为 1： 15〜1 :25 , 所述西达本胺与氢 氧化钠溶液的重量比为 1： 1.5〜1 :2.0。
3、权利要求 1所述的西达本胺晶型 A在制备用于治疗与细胞分化和增殖 相关的疾病的药物中的应用。
4、 西达本胺晶型 B, 其特征在于， 其 X-射线粉末衍射图在反射角 2Θ约 4.18°、 8.43 °、 12.65 °、 16.90°、 17.83°、 19.47 °、 20.13 °、 20.58 °、 21.22 °、 21.54 。、 21.92。、 23.94° 、 25.55。、 26.98。、 27.92。、 29.58。和 29.90。处有特征峰; 其红外光谱在约 3412、 3327、 3272、 3196、 3043、 1653、 1619、 1570、 1515、 1496、 1444、 1419、 1331、 1357、 1296、 1278、 1267、 1232、 1198、 1184、 1166 和 1038cm-1处有特征吸收峰； 其差示扫描量热分析曲线在约 214.1 °C 和 241.2°C处有吸热峰。
5、 权利要求 4所述的西达本胺晶型 B的制备方法， 其特征在于， 将西达 本胺晶型 A加入二曱基亚砜中， 室温搅拌溶解， 然后滴加水， 搅拌 30分钟， 过滤， 收集所得固体干燥即得； 其中， 所述西达本胺晶型 A与二曱基亚砜的 重量比 1： 10〜1:20, 所述西达本胺晶型 A与水的重量比为 1：屬〜 1 :200。
6、权利要求 4所述的西达本胺晶型 B在制备用于治疗与细胞分化和增殖 相关的疾病的药物中的应用。
7、一种用于治疗与细胞分化和增殖相关的疾病的药用制剂，其特征在于， 包括权利要求 1所述西达本胺晶型 A或 /和权利要求 4所述西达本胺晶型 B以 及药用辅料。
PCT/CN2012/086841 2012-11-27 2012-12-18 西达本胺的晶型及其制备方法与应用 WO2014082354A1 (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SI201231417T SI2930169T1 (sl) 2012-11-27 2012-12-18 Kristalna oblika hidamida, pripravljalni postopek in njena uporaba
CA2891006A CA2891006C (en) 2012-11-27 2012-12-18 Crystal form of chidamide, preparation method and use thereof
DK12889061.3T DK2930169T3 (en) 2012-11-27 2012-12-18 CRYSTAL FORM OF CHIDAMIDE, METHOD OF PREPARATION AND APPLICATION OF IT
JP2015543237A JP6387011B2 (ja) 2012-11-27 2012-12-18 チダミドの結晶形、その調製法および使用
ES12889061.3T ES2691395T3 (es) 2012-11-27 2012-12-18 Forma cristalina de chidamida, procedimiento de preparación y uso de la misma
EP12889061.3A EP2930169B1 (en) 2012-11-27 2012-12-18 Crystal form of chidamide, preparation method and use thereof
RU2015123682/04A RU2603138C1 (ru) 2012-11-27 2012-12-18 Кристаллическая форма хидамида, способ ее получения и применение
RS20181175A RS57856B1 (sr) 2012-11-27 2012-12-18 Kristalni oblik hidamida, postupak dobijanja i njegova upotreba
US14/646,371 US9573901B2 (en) 2012-11-27 2012-12-18 Crystal form of chidamide, preparation method and use thereof
KR1020157014782A KR20150082490A (ko) 2012-11-27 2012-12-18 차이다마이드의 결정형, 이의 제조 방법 및 용도
BR112015011898-4A BR112015011898B1 (pt) 2012-11-27 2012-12-18 Forma cristalina a da chidamida, método para preparar a forma cristalina a da chidamida, uso da forma cristalina a da chidamida e formulação farmacêutica para o tratamento de doenças relacionadas à diferenciação e proliferação celular
PL12889061T PL2930169T3 (pl) 2012-11-27 2012-12-18 Krystaliczna postać chidamidu, sposób jej wytwarzania i zastosowanie
AU2012395573A AU2012395573C1 (en) 2012-11-27 2012-12-18 Crystal form of Chidamide, preparation method and use thereof
HK15111090.9A HK1210176A1 (zh) 2012-11-27 2015-11-11 西達本胺的晶型及其製備方法與應用
HRP20181704TT HRP20181704T1 (hr) 2012-11-27 2018-10-18 Kristalni oblik kidamida, metoda pripreme i uporabe istog

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210489178.8 2012-11-27
CN201210489178.8A CN103833626B (zh) 2012-11-27 2012-11-27 西达本胺的晶型及其制备方法与应用

Publications (1)

Publication Number Publication Date
WO2014082354A1 true WO2014082354A1 (zh) 2014-06-05

Family

ID=50797567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/086841 WO2014082354A1 (zh) 2012-11-27 2012-12-18 西达本胺的晶型及其制备方法与应用

Country Status (19)

Country Link
US (1) US9573901B2 (zh)
EP (1) EP2930169B1 (zh)
JP (1) JP6387011B2 (zh)
KR (1) KR20150082490A (zh)
CN (1) CN103833626B (zh)
AU (1) AU2012395573C1 (zh)
BR (1) BR112015011898B1 (zh)
CA (1) CA2891006C (zh)
DK (1) DK2930169T3 (zh)
ES (1) ES2691395T3 (zh)
HK (1) HK1210176A1 (zh)
HR (1) HRP20181704T1 (zh)
HU (1) HUE040649T2 (zh)
PL (1) PL2930169T3 (zh)
PT (1) PT2930169T (zh)
RS (1) RS57856B1 (zh)
RU (1) RU2603138C1 (zh)
SI (1) SI2930169T1 (zh)
WO (1) WO2014082354A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046765A1 (en) * 2019-09-11 2021-03-18 Gnt Biotech & Medicals Corporation An anticancer combination of chidamide and celecoxib
US11878009B2 (en) 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN107868044B (zh) * 2016-09-27 2020-10-16 深圳微芯生物科技股份有限公司 一种非溶剂化晶体及其制备方法与应用
CN109985039A (zh) * 2017-12-29 2019-07-09 深圳微芯生物科技股份有限公司 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途
CN111195251A (zh) * 2018-11-20 2020-05-26 深圳微芯生物科技股份有限公司 西达本胺的应用
CN111195249B (zh) 2018-11-20 2023-11-28 深圳微芯生物科技股份有限公司 西达本胺联合r-chop的应用及联合药物
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
CN117597124A (zh) * 2021-07-08 2024-02-23 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗乳腺癌的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1513839A (zh) * 2003-07-04 2004-07-21 深圳微芯生物科技有限责任公司 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
WO2004071400A2 (en) * 2003-02-14 2004-08-26 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071400A2 (en) * 2003-02-14 2004-08-26 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
CN1513839A (zh) * 2003-07-04 2004-07-21 深圳微芯生物科技有限责任公司 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2930169A4
YIN, ZIHU I ET AL.: "Synthesis of chidamide, a new histone deacetylase (HDAC) inhibitor", CHINESE JOURNAL OF NEW DRUGS, vol. 13, no. 6, 2004, pages 536 - 538, XP001538889 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878009B2 (en) 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
WO2021046765A1 (en) * 2019-09-11 2021-03-18 Gnt Biotech & Medicals Corporation An anticancer combination of chidamide and celecoxib
CN114786672A (zh) * 2019-09-11 2022-07-22 华上生技医药股份有限公司 西达本胺(Chidamide)及塞来昔布(Celecoxib)的抗癌组合

Also Published As

Publication number Publication date
RU2603138C1 (ru) 2016-11-20
DK2930169T3 (en) 2018-11-12
EP2930169A4 (en) 2016-06-08
KR20150082490A (ko) 2015-07-15
US20150299126A1 (en) 2015-10-22
AU2012395573B2 (en) 2016-11-17
AU2012395573C1 (en) 2017-10-05
CA2891006A1 (en) 2014-06-05
RS57856B1 (sr) 2018-12-31
EP2930169A1 (en) 2015-10-14
CN103833626B (zh) 2015-11-25
CN103833626A (zh) 2014-06-04
US9573901B2 (en) 2017-02-21
EP2930169B1 (en) 2018-07-18
PT2930169T (pt) 2018-10-30
CA2891006C (en) 2017-06-06
JP2016500081A (ja) 2016-01-07
SI2930169T1 (sl) 2018-11-30
JP6387011B2 (ja) 2018-09-05
HRP20181704T1 (hr) 2018-12-28
HK1210176A1 (zh) 2016-04-15
BR112015011898B1 (pt) 2021-11-16
HUE040649T2 (hu) 2019-03-28
ES2691395T3 (es) 2018-11-27
PL2930169T3 (pl) 2018-12-31
AU2012395573A1 (en) 2015-06-25
BR112015011898A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
JP5934204B2 (ja) Ｃ−ｍｅｔ調節剤の薬学的組成物
JP7253491B2 (ja) キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
EP3565542B1 (en) Polymorphic forms of rad1901-2hcl
WO2018108101A1 (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
JP6727419B2 (ja) ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
JP2022000451A (ja) ピリジノイルピペリジン５−ｈｔ１ｆアゴニストに関する組成物および方法
US11643385B2 (en) Polymorphic forms of RAD1901-2HCl
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
CN108640910A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
WO2021000687A1 (zh) Pac-1晶型的制备方法
WO2014193881A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2012003413A1 (en) Novel solid forms of tacedinaline
CN111330018B (zh) 沃替西汀-环糊精包合物、制备方法及其药物组合物
CN103880833B (zh) 达沙替尼一水合物的新晶形及其制备方法和药物组合物
CN116410134A (zh) 一种罗沙司他水合物晶体及其制备方法和应用
CN106543168A (zh) 一种稳定的盐酸鲁拉西酮水合物化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12889061

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2891006

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14646371

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012889061

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015543237

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015011898

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157014782

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201503353

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2012395573

Country of ref document: AU

Date of ref document: 20121218

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015123682

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015011898

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150522